Mark Bach

Mark Bach serves as the Chief Medical Officer at GentiBio since October 2024, following previous roles as a Pharmaceutical Executive at two short-term positions in September 2024 and Chief Medical Officer at Structure Therapeutics from June 2021 to September 2024. Prior to these roles, Mark was the Senior Vice President for Clinical Development and Medical Affairs in Endocrinology at Ascendis Pharma A/S from November 2020 to June 2021. Mark's extensive experience includes significant leadership roles at Johnson and Johnson from January 2010 to November 2020, overseeing R&D and medical affairs in Asia Pacific, and at Merck from June 1993 to January 2010, managing global clinical research operations. Early career highlights include a fellowship and postdoctoral research in Pediatric Endocrinology at the NIH from July 1988 to June 1993. Mark holds an MD from Baylor College of Medicine, a PhD in Immunology from The University of Chicago Pritzker School of Medicine, and a BA in Chemistry from Carleton College.